Orally delivered deferiprone was also shown to lessen the loss of tyrosine hydroxylase cells in the substantia nigra zone in mice exposed to the Parkinson’s-inducing agent MPTP (1-methyl-4-phenyl-1,2,3,6-tetrapyridine); this protection was approximately twice that offered by intraperitoneal administration of deferoxamine (Devos et al., 2013). This evidence concerns the gene TH and Parkinsonism.